Version v2 of our SaaS platform released!

Version v2 of our SaaS platform released!

We are happy to announce that Mind the Byte has released the new v2 version of our SaaS platform for computational drug discovery! In this new version you will find updated AI algorithms and databases, new technologies and an improvement of the User Experience (UX)....
New alliance with IGTP to computationally model immune responses

New alliance with IGTP to computationally model immune responses

Mind the Byte is partnering with Germans Trias i Pujol Research Institute (IGTP) to work on the characterization and binding analysis of an immunostimulant agent. This is known to trigger T-cell activation, which is crucial for the initiation and regulation of the...
New target of Metformin revealed

New target of Metformin revealed

Metformin, the first drug chosen to be tested in a clinical trial aimed to target the biology of aging per se, has been clinically exploited for decades in the absence of a complete understanding of its therapeutic targets or chemical determinants. Now, with the...
A new therapy proves effective against brain metastasis

A new therapy proves effective against brain metastasis

A study published in Nature Medicine by a team led by researchers at the Spanish National Cancer Research Centre (CNIO), with the participation of Mind the Byte, shows that the administration of silibinin in patients with brain metastasis reduces lesions without...